Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erick H Turner

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
CNS Drugs|May 23, 2013
Publication bias, with a focus on psychiatry: causes and solutionsErick H Turner
Medical Hypotheses|May 17, 2005
5-Hydroxytryptophan plus SSRIs for interferon-induced depression: synergistic mechanisms for normalizing synaptic serotoninErick H Turner, Aaron D Blackwell
Plos Medicine|March 27, 2012
Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration databaseErick H Turner, Daniel Knoepflmacher, Lee Shapley
Psychological Medicine|October 19, 2023
Unpublished trials of alprazolam XR and their influence on its apparent efficacy for panic disorderRosa Y Ahn-Horst, Erick H Turner
Pharmacology & Therapeutics|July 19, 2005
Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophanErick H Turner, Jennifer M Loftis, Aaron D Blackwell
Plos Medicine|August 9, 2021
An open science pathway for drug marketing authorization-Registered drug approvalFlorian Naudet, Maximilian Siebert, Rémy Boussageon, et al.
Psychological Medicine|September 29, 2018
Hiding negative trials by pooling them: a secondary analysis of pooled-trials publication bias in FDA-registered antidepressant trialsYmkje Anna de Vries, Annelieke M Roest, Erick H Turner, et al.
The New England Journal of Medicine|January 18, 2008
Selective publication of antidepressant trials and its influence on apparent efficacyErick H Turner, Annette M Matthews, Eftihia Linardatos, et al.
JAMA Psychiatry|June 24, 2026
Assessing Drug Efficacy After Multiple Negative Trials-Gepirone's Journey Through the FDAErick H Turner, John H Powers, Rosa Y Ahn-Horst, et al.
Depression and Anxiety|March 29, 2014
What is the threshold for a clinically relevant effect? The case of major depressive disordersPim Cuijpers, Erick H Turner, Sander L Koole, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
CNS Drugs|May 23, 2013
Publication bias, with a focus on psychiatry: causes and solutionsErick H Turner
Medical Hypotheses|May 17, 2005
5-Hydroxytryptophan plus SSRIs for interferon-induced depression: synergistic mechanisms for normalizing synaptic serotoninErick H Turner, Aaron D Blackwell
Plos Medicine|March 27, 2012
Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration databaseErick H Turner, Daniel Knoepflmacher, Lee Shapley
Psychological Medicine|October 19, 2023
Unpublished trials of alprazolam XR and their influence on its apparent efficacy for panic disorderRosa Y Ahn-Horst, Erick H Turner
Pharmacology & Therapeutics|July 19, 2005
Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophanErick H Turner, Jennifer M Loftis, Aaron D Blackwell
Plos Medicine|August 9, 2021
An open science pathway for drug marketing authorization-Registered drug approvalFlorian Naudet, Maximilian Siebert, Rémy Boussageon, et al.
Psychological Medicine|September 29, 2018
Hiding negative trials by pooling them: a secondary analysis of pooled-trials publication bias in FDA-registered antidepressant trialsYmkje Anna de Vries, Annelieke M Roest, Erick H Turner, et al.
The New England Journal of Medicine|January 18, 2008
Selective publication of antidepressant trials and its influence on apparent efficacyErick H Turner, Annette M Matthews, Eftihia Linardatos, et al.
JAMA Psychiatry|June 24, 2026
Assessing Drug Efficacy After Multiple Negative Trials-Gepirone's Journey Through the FDAErick H Turner, John H Powers, Rosa Y Ahn-Horst, et al.
Depression and Anxiety|March 29, 2014
What is the threshold for a clinically relevant effect? The case of major depressive disordersPim Cuijpers, Erick H Turner, Sander L Koole, et al.
Pageof 4